Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity

• Published in: Mediators of inflammation Vol. 2020; no. 2020; pp. 1 - 8
• Main Authors: Wang, Guochun, Li, Sizhao, Ge, Yongpeng, Liu, Xia, Shu, Xiaoming, He, Linrong, Lu, Xin
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Adult; Age; Arthritis, Rheumatoid - blood; Autoimmune diseases; Autoimmune Diseases - blood; Biomarkers - blood; Blood tests; Clinical medicine; Comparative analysis; Dermatomyositis; Dermatomyositis - blood; Dermatomyositis - pathology; Disease; Electronic medical records; Ferritin; Humans; Inflammation; Inflammatory diseases; Interleukin 2; Interleukin 2 receptors; Interleukins; Laboratories; Lymphocytes; Lymphocytes T; Male; Medical prognosis; Middle Aged; Musculoskeletal diseases; Myopathy; Myositis; Pathogenesis; Patients; Receptors, Interleukin-2 - blood; Rheumatoid arthritis; Rheumatoid factor; Skin; Skin diseases; Skin lesions; Skin Ulcer - blood; Skin Ulcer - pathology; Somatotropin; Studies; Systemic lupus erythematosus; T cells; Ulcers; China; Japan
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2020/6243019

Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), and 20 healthy controls (HCs) by chemiluminescent immunometric assay. Clinical features and laboratory data were collected from electronic medical record. Disease activity was evaluated by using physician global disease activity and myositis disease activity assessment visual analog scale (MYOACT) on admission. 20 DM patients were followed. Serum sIL-2R levels were analyzed and compared with clinical features, laboratory data, and measures of disease activity. Results. Serum sIL-2R levels were significantly higher in DM patients than in IMNM patients and HCs (648.8±433.1 U/ml vs. 352.3±126.0 U/ml and 648.8±433.1 U/ml vs. 285.8±101.9 U/ml, respectively; all P<0.001), while there was no significant difference between IMNM and HCs. There were also no significant differences of sIL-2R levels in DM, SLE, and RA. Importantly, serum sIL-2R levels were significantly higher in treatment-naïve or active DM patients than those that are not (1100.9±550.4 U/ml vs. 615.6±330.4 U/ml, P=0.006; 808.8±421.6 U/ml vs. 339.8±103.4 U/ml, P<0.001). DM patients with skin ulcers had significantly higher sIL-2R levels than those without (889.3±509.9 U/ml vs. 640.0±368.7 U/ml, P=0.023). Cross-sectional analysis in DM showed that sIL-2R levels positively correlated with CK, ESR, CRP, ferritin, physician VAS, and MYOACT scores (rho=0.278, rho=0.474, rho=0.469, rho=0.454, r=0.646, and r=0.600, respectively; all P<0.05), negatively correlated with T cell counts and MMT8 scores (r=−0.380, P=0.002; rho=−0.394, P=0.001). Follow-up study showed that changes in sIL-2R levels after treatment correlated with changes in physician VAS and MYOACT scores (r=0.823 and r=0.695, respectively; all P<0.01). Conclusion. Serum sIL-2R levels were elevated in DM but not in IMNM. Serum sIL-2R could act as a disease activity marker and be associated with ulcerative skin lesions in DM.